An additional study on rindopepimut was completed in 72 recurrent GBM patients in a phase II trial, termed “ReACT” (NCT01498328), combining the vaccine with bevacizumab, a monoclonal antibody against VEGF that has been shown to enhance immune responses [34]. The gene discussed is VEGFA; the disease is glioblastoma.